CALA - Calithera Biosciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.50
-0.20 (-4.26%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close4.70
Open4.65
Bid4.40 x 1000
Ask5.00 x 1000
Day's Range4.40 - 4.65
52 Week Range4.05 - 18.35
Volume316,200
Avg. Volume379,531
Market Cap161.943M
Beta3.18
PE Ratio (TTM)N/A
EPS (TTM)-1.00
Earnings DateNov 7, 2017 - Nov 13, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.25
Trade prices are not sourced from all markets
  • GlobeNewswire4 days ago

    Recent Analysis Shows Ellie Mae, Organovo, Calithera Biosciences, Whirlpool, Marathon Oil, and Infinera Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, Aug. 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ellie ...

  • Calithera (CALA) Reports Q2 Loss, Tops Revenue Estimates
    Zacks11 days ago

    Calithera (CALA) Reports Q2 Loss, Tops Revenue Estimates

    Calithera (CALA) delivered earnings and revenue surprises of 72.73% and 230.40%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press11 days ago

    Calithera: 2Q Earnings Snapshot

    The South San Francisco, California-based company said it had a loss of 9 cents per share. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • GlobeNewswire11 days ago

    Calithera Biosciences Reports Second Quarter 2018 Financial Results and Recent Highlights

    -Two Novel Programs Entering Clinical Development. -Calithera to Host Conference Call Today at 2:00 p.m. Pacific Time/ 5:00 p.m. Eastern Time. SOUTH SAN FRANCISCO, Calif., Aug. 07, 2018-- Calithera Biosciences, ...

  • ACCESSWIRE11 days ago

    Calithera Biosciences, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Calithera Biosciences, Inc. (NASDAQ: CALA ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 5:00 PM Eastern ...

  • GlobeNewswire17 days ago

    Calithera Biosciences to Report Second Quarter 2018 Financial Results on Tuesday, August 7, 2018

    Calithera Biosciences, Inc. (CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced that the Company’s second quarter 2018 financial results will be released on Tuesday, August 7, 2018. Company management will host a conference call on Tuesday, August 7, 2018 at 2:00 p.m. Pacific Time/ 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights. The press release and live audio webcast can be accessed via the Investor section of the Company’s website at www.calithera.com.

  • ACCESSWIRE2 months ago

    Complimentary Technical Snapshots on Celgene and Three More Biotech Stocks

    Four stocks have been lined up for today's assessment, and they are: Calithera Biosciences Inc. (CALA), Cara Therapeutics Inc. (CARA), Celgene Corp. (CELG), and Celldex Therapeutics Inc. (CLDX). Shares in South San Francisco, California headquartered Calithera Biosciences Inc. jumped 5.53%, ending Wednesday's trading session at $5.25. The stock recorded a trading volume of 552,298 shares, which was higher than its three months average volume of 426,620 shares.

  • GlobeNewswire2 months ago

    Calithera to Present at the Jefferies and JMP Securities Healthcare Conferences in June

    SOUTH SAN FRANCISCO, Calif., June 06, 2018-- Calithera Biosciences, Inc., a clinical stage biotechnology company focused on the development of novel cancer therapeutics, announced today Susan M. Molineaux, ...

  • GlobeNewswire2 months ago

    Results from Phase 1 Study of CB-839 in Combination with Capecitabine in Advanced Solid Tumors to be Presented at the 2018 American Society of Clinical Oncology (ASCO)

    Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on the development of novel cancer therapeutics, announced today that clinical data from its lead product candidate CB-839, a novel glutaminase inhibitor, will be presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held from June 1 to June 5, 2018 in Chicago, Illinois. This is the first presentation of the Case Western investigator-sponsored phase 1/2 trial evaluating CB-839 in combination with capecitabine in patients with treatment refractory advanced solid tumors. The combination demonstrated a median progression free survival of 26 weeks in seven patients with treatment-refractory advanced colorectal cancer harboring a PIKC3A mutation who had disease progression on at least one prior fluoropyrimidine-containing regimen.

  • Calithera Biosciences Inc (NASDAQ:CALA): Is Breakeven Near?
    Simply Wall St.3 months ago

    Calithera Biosciences Inc (NASDAQ:CALA): Is Breakeven Near?

    Calithera Biosciences Inc’s (NASDAQ:CALA): Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets forRead More...

  • Associated Press3 months ago

    Calithera: 1Q Earnings Snapshot

    On a per-share basis, the South San Francisco, California-based company said it had a loss of 37 cents. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...

  • Biotech Stock Roundup: PRTA Down, AMGN Revises View, BIIB Misses on Sales
    Zacks4 months ago

    Biotech Stock Roundup: PRTA Down, AMGN Revises View, BIIB Misses on Sales

    The biotech sector grabbed headlines last week as a couple of biotechs reported results while few others came out with pipeline updates.

  • ACCESSWIRE4 months ago

    Blog Exposure - FDA Granted Fast Track Designation to Calithera Biosciences’ CB-839 in Combination with Cabozantinib for Advanced Renal Cell Carcinoma Treatment

    LONDON, UK / ACCESSWIRE / April 20, 2018 / Active-Investors.com has just released a free research report on Calithera Biosciences, Inc. (NASDAQ: CALA) ("Calithera"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CALA as the Company's latest news hit the wire. On April 18, 2018, the San Francisco-based biopharmaceutical Company announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to the Company's lead product candidate, CB-839, in combination with cabozantinib for the treatment of patients with metastatic renal cell carcinoma (RCC) who have received one or two prior lines of therapy, including at least one vascular endothelial growth factor tyrosine kinase inhibitor or the combination of nivolumab and ipilimumab.

  • Calithera's Kidney Cancer Candidate Gets Fast Track Status
    Zacks4 months ago

    Calithera's Kidney Cancer Candidate Gets Fast Track Status

    Calithera Biosciences' (CALA) lead pipeline candidate, CB-839, gets fast track status in the United States for the treatment of kidney cancer.

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of CALA earnings conference call or presentation 8-Mar-18 9:30pm GMT

    Q4 2017 Calithera Biosciences Inc Earnings Call

  • Does Calithera Biosciences Inc’s (NASDAQ:CALA) Latest Financial Perfomance Look Strong?
    Simply Wall St.5 months ago

    Does Calithera Biosciences Inc’s (NASDAQ:CALA) Latest Financial Perfomance Look Strong?

    Assessing Calithera Biosciences Inc’s (NASDAQ:CALA) past track record of performance is a valuable exercise for investors. It enables us to reflect on whether the company has met or exceed expectations,Read More...

  • Associated Press5 months ago

    Calithera reports 4Q loss

    On a per-share basis, the South San Francisco, California-based company said it had a loss of 31 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed ...